Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.83	$1.21	$0.66 ▼ $3.00	$170.20M	2.48	1.29 million shs	1.64 million shs
MNMD Mind Medicine (MindMed)	$8.88 +3.5%	$7.20	$4.70 ▼ $10.44	$670.91M	2.45	1.33 million shs	1.04 million shs
UPB Upstream Bio	$11.04 +1.1%	$10.40	$5.14 ▼ $29.46	$593.89M	N/A	351,900 shs	561,208 shs
XNCR Xencor	$9.07 +2.7%	$8.48	$7.16 ▼ $27.24	$645.51M	0.85	683,751 shs	427,942 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	+13.66%	+4.57%	+63.39%	+148.98%	-32.97%
MNMD Mind Medicine (MindMed)	+6.32%	+11.14%	+20.17%	+48.70%	+1.06%
UPB Upstream Bio	-1.97%	-6.67%	-2.24%	+24.37%	+1,091,999,900.00%
XNCR Xencor	+4.62%	-5.36%	-2.43%	-8.97%	-56.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.9343 of 5 stars	3.5	3.0	0.0	3.2	1.7	0.6
MNMD Mind Medicine (MindMed)	2.1123 of 5 stars	3.6	1.0	0.0	2.9	0.8	0.6
UPB Upstream Bio	1.7849 of 5 stars	3.5	0.0	0.0	1.6	0.8	0.6
XNCR Xencor	4.4341 of 5 stars	3.4	5.0	3.9	2.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$8.50	355.76% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	190.27% Upside
UPB Upstream Bio	3.00	Buy	$56.50	414.57% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	207.69% Upside

Current Analyst Ratings Breakdown

Latest CRBU, UPB, XNCR, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.92M	17.49	N/A	N/A	$2.79 per share	0.67
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
UPB Upstream Bio	$2.30M	257.26	N/A	N/A	$8.77 per share	1.25
XNCR Xencor	$110.49M	5.86	N/A	N/A	$9.63 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest CRBU, UPB, XNCR, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.37	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	UPB Upstream Bio	-$0.61	N/A	N/A	N/A	$0.32 million	N/A
8/4/2025	Q2 2025	XNCR Xencor	-$0.78	N/A	N/A	N/A	$22.59 million	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.63	7.63
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
UPB Upstream Bio	N/A	47.43	47.43
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
MNMD Mind Medicine (MindMed)	27.91%
UPB Upstream Bio	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
MNMD Mind Medicine (MindMed)	2.45%
UPB Upstream Bio	13.56%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.01 million	85.30 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A
XNCR Xencor	280	71.17 million	67.78 million	Optionable

CRBU, UPB, XNCR, and MNMD Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

July 3, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17, 2025 | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

Xencor participates in a conference call with JPMorgan

April 18, 2025 | markets.businessinsider.com

Xencor, Inc.: No Major Near Term Catalysts

April 11, 2025 | seekingalpha.com

Xencor (XNCR) Upgraded to Buy: Here's Why

April 10, 2025 | zacks.com

Xencor’s SWOT analysis: biotech stock faces pivotal year ahead

April 10, 2025 | uk.investing.com

Barclays Keeps Their Sell Rating on Xencor (XNCR)

April 3, 2025 | markets.businessinsider.com

The Court of Appeals for the Federal Circuit’s In Re Xencor Decision: Jepson Claims Require Written Description for Their Preambles

March 24, 2025 | jdsupra.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, UPB, XNCR, and MNMD Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.83 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.83 0.00 (0.00%)

As of 07:09 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$8.88 +0.30 (+3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$8.79 -0.09 (-1.01%)

As of 07:10 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Upstream Bio NASDAQ:UPB

$11.04 +0.12 (+1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$11.02 -0.01 (-0.14%)

As of 04:04 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Xencor NASDAQ:XNCR

$9.07 +0.24 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$8.98 -0.09 (-0.98%)

As of 05:33 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time